ASSOCIATION OF TORULOPSIS-GLABRATA INFECTIONS WITH FLUCONAZOLE PROPHYLAXIS IN NEUTROPENIC BONE-MARROW TRANSPLANT PATIENTS

Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The Johns Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5%) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75%) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.